India s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has discovered the widespread use of industrial-grade excipients, unfit for human consumption, in the country s pharmaceutical manufacturing. Following international complaints, the CDSCO conducted investigations and inspections, revealing that unlicensed traders supplied industrial-grade gelatin, propylene glycol, and other excipients to pharmaceutical manufacturing units.
The Drugs Controller General of India (DCGI) is considering banning over-the-counter (OTC) sales of pain relievers Tapentadol and Pregabalin to curb misuse. Pregabalin is prescribed for neuropathic pain and fibromyalgia, while Tapentadol is used for seizures. The DCGI has constituted a sub-committee to review the matter, including experts from the regulator s office, clinicians, and pharmacologists.
Close on the heels of Sonepat-based Maiden Pharma’s cough and cold syrups attracting WHO’s global medical alert over links to the deaths of more than 66 Gambian children, the Government on Tuesday informed the Rajya Sabha that 36 banned drugs were licensed by different state drug regulat